This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Mahadeo, K. M. et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(23)00649-6 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Tabelecleucel is effective in EBV-positive lymphoproliferative disease. Nat Rev Clin Oncol 21, 251 (2024). https://doi.org/10.1038/s41571-024-00873-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-024-00873-3